- EMEA Innovative Medicine
- How we work
- Transparency
- J&J Innovative Medicine Disclosure Methodology
J&J Innovative Medicine Disclosure Methodology
- Fees for service and reimbursements for Out-of-pocket costs, Donations, Grants Sponsorships to HCOs and financial support to Patient Organisations (POs) will be included in the calendar year in which we executed the actual payment or reimbursement in our financial systems.
- Transfers of value related to travel (e.g. flight ticket), accommodation (e.g. hotel room cost) and registration fees, will be included in the calendar year during which the activity occurred.
- In case of payments through a third party, our payment date to the third party is used as the determining factor to allocate the payment to the related calendar year.
Each of these separate payments will be included in the calendar year in which we executed the actual payment or reimbursement in our financial systems.
All TOVs from services or products (e.g. flight ticket, hotel room, …) are reported gross, so inclusive of VAT (and tips) when applicable.
The disclosure reported TOV amounts should not be used for any VAT/Tax reporting purposes. If fiscal reports are required, the company provides them directly to the HCPs/HCOs & POs.
For TOVs that were originally made in non-local currency, a conversion to local currency is made and exchange rate details can be provided on a case by case basis.
According to individual privacy rights, consent to individual disclosure can be withdrawn by HCPs, in which case disclosure is made on an aggregate basis. We apply Consent or withdrawal of consent per HPC for all TOVs for a given year.
R&D TOVs are TOVs to HCPs or HCOs related to the planning or conduct of (i) non-clinical studies (as defined in OECD Principles on Good Laboratory Practice); (ii) clinical trials (as defined in Directive 2001/20/EC); or (iii) non-interventional studies that are prospective in nature and that involve the collection of patient data from or on behalf of individual, or groups of, HCPs specifically for the study (Section 15.01 of the HCP Code).
Disclaimer
We rely on a combination of automated systems, standardized processes, and manual data entry from internal and external resources to record relevant data and finally report it. The information reported in this submission reflects our good faith and best efforts to comply with the requirements of the EFPIA Disclosure Code. Should we, despite our best efforts to ensure accurate reporting, fail to include complete and correct information in our submission, we will appropriately investigate and address in case of erroneous information.
The TOVs disclosed as per EFPIA requirements and on this site, are only used to meet the EFPIA reporting requirements. The costs are not to be used as backup for any TAX Authority Reporting, or any other reporting similar to this.
CP-459038
September 2024